A monoclonal antibody that inhibits IL-4R signaling, approved for atopic dermatitis and other inflammatory conditions.
Dupixent (dupilumab) is a human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, inhibiting signaling of both cytokines. It is approved for the treatment of moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis.
Developed by Regeneron and marketed by Sanofi, Dupixent has become a standard of care for multiple type 2 inflammatory diseases and is one of the leading biologics for atopic dermatitis worldwide.
AbCellera Biologics
Abcl575
abcellera.com
Enveda Biosciences
ENV-294
enveda.com
Galderma
Therapeutic Dermatology
galderma.com
Triveni Bio
Triv-509, Triv-573
triveni.bio
| Attribute | Dupixent | Abcl575 | ENV-294 | Therapeutic Dermatology | Triv-509, Triv-573 | |
|---|---|---|---|---|---|---|
| Provider | | | | | | |
| Founded | 1973 | 2012 | 2019 | 1981 | 2023 | |
| Sells To | Enterprise | Enterprise, Government | Enterprise | B2B, B2C | B2B, Enterprise | |
| Pricing Model | Recurring | Recurring, Software | Recurring | Product Sales | Licensing, Pre-Revenue | |
| Ownership | Public | Public | Venture-backed | Public | Private, Venture-backed |
Provider
Founded 1973
Sells To Enterprise
Pricing Model Recurring
Ownership Public
Provider
Founded 2012
Sells To Enterprise, Government
Pricing Model Recurring, Software
Ownership Public
Provider
Founded 2019
Sells To Enterprise
Pricing Model Recurring
Ownership Venture-backed
Provider
Founded 1981
Sells To B2B, B2C
Pricing Model Product Sales
Ownership Public
Provider
Founded 2023
Sells To B2B, Enterprise
Pricing Model Licensing, Pre-Revenue
Ownership Private, Venture-backed
A selective IL-13 inhibitor approved for atopic dermatitis in patients aged six and older.
A selective IL-13 inhibitor approved for atopic dermatitis in patients aged six and older.
Rinvoq is a AbbVie product.
Opzelura is a Incyte product.